Hepatitis C virus (HCV) is recognised as one of the major infectious causes of liver disease worldwide and is a leading cause of liver-related morbidity and mortality. In India, hepatitis B virus (HBV) infections account for one-third of hepatocellular carcinoma (HCC) burden and HCV infection contributes to another one-third of HCC cases. [1] The prevalence of HCV infection in India was estimated to be around 1%-1.9%. [2] Chronic hepatitis C infection was observed in 70%-85% of people who had acute hepatitis C infection leading to chronic liver diseases such as cirrhosis and HCC. [3] Among those with chronic infection, almost one-third develop cirrhosis manifesting 1%-4% annual risk of developing end-stage liver disease and HCC. [4] Most of the prevalence studies from India were carried out in selected groups undergoing dialysis, immunocompromised individuals, intravenous drug users or blood donors. The estimates obtained from these studies have been extrapolated onto the general population which may not be representative of the HCV prevalence. In the public health perspective, community-based studies can provide information regarding the various modes of transmission of this hepatotropic virus facilitating the adoption of various preventive measures. In this cross-sectional study, we report the seroprevalence of HCV among acute febrile illness (AFI) cases in Idar Taluk, Sabarkantha district, Gujarat, West India.
and approved by the Institutional Ethical Committee, Manipal Academy of Higher Education (IEC No: UEC/32/2013-14, MUEC/Renewal-08/2017). All the fever cases of <2 weeks duration within the age group of 1-65 years from Idar Taluk, Gujarat, were included. The screening for anti-HCV IgG antibody was performed using commercially available third-generation enzyme-linked immunosorbent assay (ELISA) kit (Erba Lisa by Transasia Bio-Medicals Ltd., India) which utilises the combination of recombinant proteins of HCV such as Core, NS3, NS4 and NS5 for the detection of anti-HCV IgG antibodies. The samples screened positive for Anti-HCV antibodies were further tested by polymerase chain reaction (PCR). The viral RNA was extracted using the QIAamp ® Viral RNA Mini Kit (QIAGEN, Germany) as per the manufacturer's instructions.
HCV RNA amplification was performed by reverse-transcription real-time PCR (Fast Track Diagnostics Luxembourg) targeting the 5'untranslated region. The positive samples were genotyped by conventional nested PCR targeting the HCV core gene. [5] The extracted nucleic acid (5 µl RNA) was added to the 20 µl first-round reaction mixture containing 12.5 µl buffer mix (Ambion ® Life Technologies, USA), 1 µl each of primers (Sc2, Ac2), 1 µl of Enzyme mix (Ambion Life Technologies ® , USA) and 4.5 µl nuclease-free water. The amplification was carried out in the ProFlex ™ PCR system (Life Technologies, USA). The reverse transcription was carried out at 50°C for 30 min and initial denaturation at 95°C for 10 min. The amplification of cDNA was carried out by 40 cycles of denaturation (95°C for 45 s), primer annealing (50°C for 20 s and 45°C for 20 s) and primer extension (68°C, for 1 min) and final extension at 68°C for 5 min. The first-round product 9.5 µl was added to the reaction mixture containing 12.5 µl of buffer mix (Ambion ® Life Technologies, USA), 1 µl each of primers (S7, A5) and 1 µl of Enzyme mix (Ambion Life Technologies ® , USA). The initial reverse transcription was carried at 95°C for 30 min followed by denaturation at 95°C for 30 s, annealing at 62°C for 20 s, extension (68°C for 45 s) and final extension at 68°C for 5 min. The amplified PCR product was electrophoresed in ethidium bromide-stained 1.8% (W/v) agarose gel (Merck, USA) and was purified using GenElute™ Gel purification Kit (Sigma Aldrich, USA). The purified PCR products were sequenced using Big Dye Terminator Kit (Applied Biosystems, USA), according to the manufacturer's instructions in a 3500 XL genetic analyser (Applied Biosystems, USA). The sequences were edited using MEGA 7 (MEGA version 7.0) and were compared with reference sequences in GenBank BLAST from NCBI. The phylogenetic analysis of hepatitis C strains was performed using MEGA7 software (http://www. megasoftware.net/). The phylogenetic tree was constructed using the maximum-likelihood method, and the reliability of the tree was verified by the bootstrap method (1000 replicates).
The details regarding the sociodemographic, clinical and laboratory parameters were obtained from AFI database. The confirmed hepatitis C cases were classified based on the Child-Turcotte-Pugh (CTP) classification, which helps in assessing the prognosis of chronic liver disease cases. This classification takes into consideration the liver function parameters such as total bilirubin (mg/dl), albumin (gm/dl), prothrombin time (seconds), clinical features of ascites and hepatic encephalopathy. [6] Based on the classification, patients classified under Group A has a probable 1-year survival rate of 100% and a 2-year survival rate of 85%. Meanwhile, patients belonging to Class B and C are anticipated to be having 1-year survival rates of 80% and 45% and 2-year survival rates of 60% and 35%, respectively.
Statistical analysis
The statistical analysis was carried out using the SPSS 15.0 for Windows (SPSS ™ Inc., Chicago, IL, USA). The demographic data and baseline characteristics were summarised by frequency and percentages. Meanwhile, continuous variables were represented by mean with standard deviation for normally distributed parameters and median with interquartile range (IQR) for parameters not normally distributed. Confidence intervals (CI) of 95% with continuity correction were calculated for proportions.
reSultS
During the study period, serum samples of 702 patients from Idar Taluk, Gujarat with AFI were screened by anti HCV ELISA. Among the enrolled cases, 387 (55.1%) were in the age group of 13-35 years [ Table 1 ]. The median age of the study participants was 25 years (IQR: 16-38 years). There were 406 males (57.8%) and 296 females (42.2%). Out of the 702 study participants, 433 (61.7%) belonged to low-socioeconomic status and 269 (38.3%) were grouped under middle -socioeconomic status based on modified Udai Parikh scale. [7] None of the cases presented with altered sensorium, seizures or hepatomegaly. High bilirubin level >2 mg/dl was observed in 37 cases. The liver function parameters were within the normal limits among the majority of patients.
The serum samples of 16 cases, including seven males and nine women, were screened positive for anti-HCV IgG with an estimated seroprevalence rate of 2.3% (95% CI: 1.4%-3.7%). The median age of these seropositive cases was 32.5 years (IQR: 17-39 years). Out of these, two samples were later confirmed positive for HCV RNA by PCR indicating active infection. The estimated prevalence of active HCV infection among the study participants recruited from Idar Taluk, Gujarat was 0.28% (95% CI: 0.05%-1.13%). The two hepatitis C confirmed samples were genotyped as 1b and 3a. Total bilirubin level was within the normal range among 395 (56.3%) cases of acute fever. However, bilirubin level >2 mg/dl was reported among 37 cases (5.3%) of which 14 had a bilirubin level >6 mg/dl. The levels of alanine transaminase and aspartate transaminase were within the normal limits among 415 (59.1%) and 412 (58.7%) cases, respectively [ Table 2 ]. The serum albumin below normal was observed in one patient. Out of the 16 samples which were reactive for anti-HCV IgG ELISA, three samples were PCR confirmed for influenza, malaria and shigella each and the remaining eleven samples were undiagnosed. Ten study participants belonged to low-socioeconomic status (Modified Udai Pareek scale), and six cases were from middle-socioeconomic status. Two patients were confirmed to be having current HCV infection.
The first case (Case 1) was a 50-year-old, female, manual labourer with a history of pulmonary tuberculosis. She was hospitalised 20 years back for the treatment of anaemia and had received blood transfusion. Physical examination revealed tattoo marking over her left forearm. Another confirmed case (Case 2) was a 65-year-old, male, landlord from middle socio-economic status. The patient denied any history of surgical procedures, blood transfusion, tattooing or community shaving. However, he had undergone multiple dental procedures such as tooth extractions and transplantations. Liver function parameters of both the patients were within the normal limits.
The nucleotide and deduced amino acid sequences of the HCV core gene (311 bp) of the two strains were compared with the published sequences in the NCBI nucleotide database. On phylogenetic analysis, one strain was grouped with HCV 1b, and another was clustered with HCV3a [ Figure 1 ]. The genotype 1b showed 95% sequence similarity to reference strains from Western parts of India such as Ahmedabad, Baroda and Maharashtra region. [8] The genotype 3a showed 92% sequence similarity to strains from western India and Thailand. [9] The sequences of the core gene were edited and submitted to GenBank (wwww.ncbi.nlm.nih.gov). The GenBank accession numbers of the two Idar strains were MH 922987 and MH 922988. Hence, this study area was chosen to estimate the prevalence of antibodies to HCV, another hepatotropic virus sharing similar modes of transmission. Almost three-fourths of the study participants were in the age group of 13-45 years. Two-thirds of the enrolled patients belonged to low-socioeconomic status. The liver function parameters of most of the study participants were within the normal limits. The seroprevalence was not significantly higher among males compared to women in the present cross-sectional study. Most of the previous studies from Rajasthan, north India have reported a higher prevalence estimate among males. [10] Meanwhile, a study from south India reported no gender disparity in hepatitis C prevalence and exposure to risk factors. [11] The seroprevalence of anti-HCV antibody was estimated to be 2.3% in our study, which was in accordance with previous studies from India.
Both the patients with confirmed hepatitis C infection were grouped under Class A based on CTP classification [
The estimated HCV prevalence data from various parts of India range between 0.09% and 7.9%. [12] Most of the prevalence estimates were obtained from blood banks or dialysis units. The largest population-based study from West Bengal, India, had enrolled 2973 individuals and reported an estimated prevalence of 0.87%. [13] Another community-based survey enrolling 1000 rural inhabitants from Maharashtra observed a very low prevalence 0.09% of HCV. [14] Hospital-based studies from Rajasthan and Maharashtra reported seroprevalence estimates of 0.28% and 0.46%, respectively. [10, 15] The hospital-based study carried out by Bhattacharya et al. reported a seroprevalence of 4.8% HCV infection among patients with no history of hepatitis, cirrhosis or chronic renal diseases attending a tertiary care hospital at Puducherry, south India. [11] Hospital-based seroprevalence study from East India reported prevalence estimates of 1.6% among inpatients and 2.1% among healthy voluntary blood donors. [16] The epidemiological survey from Punjab, north India reported a seroprevalence of 5.2% among the general population. This study reported a higher HCV seroprevalence with decreasing education and low income. However, HCV RNA was confirmed in serum Figure 1 : The phylogenic tree was constructed based on a 300 bp fragment encoding the partial core region of hepatitis C. The typing and subtyping of hepatitis C virus genotypes were based on the report by Lole et al. [8] The bootstrap values above 60% were shown on the major nodes. The study strains with GenBank accession numbers were shown as blue diamonds (MH922987, MH922988) samples of only 1.6% of the study participants indicating active infection. [17] Punjab province of Pakistan has also reported a very high HCV prevalence estimate indicating the existence of a hepatitis C belt inhabited by Punjabis from India as well as Pakistan. [18] The WHO targets the elimination of hepatitis C (HCV) and hepatitis B (HBV) infections by the year 2030. This can be achieved by various public health measures such as safe injection practices, safe blood banking, protected sex and HBV vaccination to prevent newly acquired infections by 90% as well as antiviral therapy to reduce the viral hepatitis-related mortality by 65%. [19] In the worst affected regions of the Middle East and North Africa, two-thirds of HCV seropositive individuals are chronically infected. [20] There are a number of limitations of this study. Even though certain high-risk behaviours were observed among the two cases with confirmed HCV infection, we could not retrieve any details regarding the high-risk behaviours from the 14 cases who showed the evidence of past infection. The history given by patients regarding previous injections from health centres may not be precise as this was based on past recall. As a result of social desirability bias, the self-reporting of intravenous drug use and exposure to unprotected sex may not be precise. We observed that people often remember and record the previous history of major illnesses, blood transfusions and surgeries.
In developing countries, there is a large pool of chronically infected patients who can serve as a source of transmission to others and are at risk of chronic liver diseases, including HCCs. In a public health perspective, multicentric laboratory-based studies can provide a platform for the development and strengthening of hepatitis surveillance programme in India.
cOncluSiOn
We conclude that the estimated seroprevalence of hepatitis C in Idar Taluk, Sabarkantha District of Gujarat, West India was 2.3%.
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